The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection
Abstract
A panel of human sera exhibited a ≥128-fold higher neutralizing potency against a human cytomegalovirus (HCMV) clinical isolate propagated and tested in endothelial (or epithelial) cells than against the same virus infecting human fibroblasts. In a group of 18 primary infections, the reverse geometric mean titre was in the range of 10–15 in human fibroblasts within the first 3 months after the onset of infection, whereas the endothelial cell infection-neutralizing activity was already present within the first 10 days, reaching median levels of 122, 320 and 545 at respectively 30, 60 and 90 days after onset, then declining slowly. This difference was also confirmed in the majority of reactivated and remote HCMV infections, as well as in a hyperimmune globulin preparation. The antibody response to HCMV pUL131A, pUL130 and pUL128 locus products, which are required for endothelial/epithelial cell infection, provided a potential molecular basis for such a differential neutralizing activity. In addition, monoclonal/monospecific antibodies raised against the pUL131A, pUL130 and pUL128 proteins were found to display an inhibitory activity on HCMV plaque formation and HCMV leukocyte transfer from HCMV-infected cells. Hence, conventional determination of the neutralizing activity of human sera in fibroblasts is misleading. Antibodies to pUL131A, pUL130 and pUL128 appear to display a major HCMV-neutralizing and dissemination-inhibiting activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerna, G., Percivalle, E., Baldanti, F., Sozzani, S., Lanzarini, P., Genini, E., Lilleri, D., & Revello, M. G. (2000) · Journal of Virology · doi:10.1128/jvi.74.12.5629-5638.2000 · Cited by 171
Self-citation
Cited by
A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
Revello, M. G., Lazzarotto, T., Guerra, B., Spinillo, A., Ferrazzi, E., Kustermann, A., Guaschino, S., Vergani, P., Todros, T., Frusca, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310214 · Cited by 489
Self-citationCytomegalovirus: pathogen, paradigm, and puzzle
Boeckh, M., & Geballe, A. P. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45449 · Cited by 357
Macagno, A., Bernasconi, N. L., Vanzetta, F., Dander, E., Sarasini, A., Revello, M. G., Gerna, G., Sallusto, F., & Lanzavecchia, A. (2010) · Journal of Virology · doi:10.1128/jvi.01809-09 · Cited by 326
Self-citationJohn, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229
(2024) · doi:10.1073/pnas.2404250121 · Cited by 37
Metadata
- Authors
- Gerna, G., Sarasini, A., Patrone, M., Percivalle, E., Fiorina, L., Campanini, G., Gallina, A., Baldanti, F., & Revello, M. G.
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2008-04-01
- Volume
- 89
- Issue
- 4
- Pages
- 853-865
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- OpenAlex
- W2095651237
- Cited by
- 179
- References
- 1
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. https://app.cochat.ai/papers/10.1099/vir.0.83523-0
- The paper
- Gerna, G., Sarasini, A., Patrone, M., Percivalle, E., Fiorina, L., Campanini, G., Gallina, A., Baldanti, F., & Revello, M. G. (2008). Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. Journal of General Virology. https://doi.org/10.1099/vir.0.83523-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.